Pharmacovigilance (PV) in China
Before 2018, the Pharmacovigilance (PV) System in China was still in its early days. Companies’ activities to drug safety were for the most part passive. Then market authorization holder (MAH) was put in place to report on adverse drug reactions (ADR). As a result, in 2019 China included the provision of “establishing…